Why is Zealand Pharma stock sliding today?

US concludes third round of strikes against Iran after Trump reinstates blockade Investing.com -- Zealand Pharma stock fell 2.0% today after Jefferies downgraded the Danish biotech from Buy to Hold and slashed its price target to DKK 320 from DKK 505 — a...

US concludes third round of strikes against Iran after Trump reinstates blockade Investing.com -- Zealand Pharma stock fell 2.0% today after Jefferies downgraded the Danish biotech from Buy to Hold and slashed its price target to DKK 320 from DKK 505 — a reduction of roughly 37% — citing the absence of near-term value-crystallising events in the second half of 2026. The firm also lowered its probability of success for survodutide, Zealand’s glucagon/GLP-1 dual agonist developed in partnership with Boehringer Ingelheim, to 40% from 60%, reflecting lingering concerns about the drug’s clinical profile following Phase III data presented at the American Diabetes Association meeting in June.

The Jefferies action reinforces a broader analyst reassessment of the survodutide franchise that began last month, when Wolfe Research also stripped its Outperform rating on tolerability concerns — specifically a placebo-adjusted patient discontinuation rate that was far higher than those seen with rival therapies from Novo Nordisk and Eli Lilly. Multiple sell-side firms, including Jefferies and UBS, have indicated that a meaningful inflection point for the stock is unlikely to arrive before 2027, leaving the near-term narrative largely dependent on progress from petrelintide, Zealand’s amylin analog being advanced into Phase 3 trials in collaboration with Roche.

On the broader market front, the OMXC25 benchmark in Copenhagen was also in negative territory today, underperforming the stock’s sector peers, while U.S. equity markets added to the risk-off tone with the S&P 500 and Nasdaq both trading lower. No company-specific earnings releases or corporate announcements from Zealand Pharma were issued on today’s date, leaving the Jefferies downgrade as the dominant driver of price action. Taken together, a high-profile analyst rating cut, a materially reduced price target, and a still-unresolved overhang from survodutide’s tolerability data combined to push Zealand Pharma shares lower today, with the stock now trading closer to its 52-week low of DKK 233.5 than to its 52-week high of DKK 556, reflecting the market’s cautious stance ahead of the next anticipated clinical readouts.